Research Article

Comparison of the Feasibility and Safety of First- versus Second-Generation AMPLATZER™ Occluders for Left Atrial Appendage Closure

Baravan Al-Kassou¹ and Heyder Omran²

¹Medizinische Klinik und Poliklinik II, Universitätsklinikum Bonn, Sigmund-Freud-Str. 25, 53127 Bonn, Germany
²GFO Kliniken Bonn, Robert-Koch-Str. 1, 53115 Bonn, Germany

Correspondence should be addressed to Baravan Al-Kassou; baravan.alkassou@uni-bonn.de and Heyder Omran; heyder.omran@marien-hospital-bonn.de

Received 6 July 2016; Revised 24 January 2017; Accepted 5 July 2017; Published 20 September 2017

A cademic Editor: Richard Houben

Copyright © 2017 Baravan Al-Kassou and Heyder Omran. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction. Left atrial appendage closure (LAAC) is considered an alternative to oral anticoagulation therapy in patients with atrial fibrillation (AF). The aim of this study was to compare the safety and efficacy of the first- and second-generation AMPLATZER Devices for LAAC, AMPLATZER Cardiac Plug (ACP) versus AMPLATZER Amulet™.

Methods. Procedural data, such as fluoroscopy time, radiation dose, and contrast-dye, as well as VARC criteria and major adverse events (MAEs) were assessed for both devices. The rate of peridevice leaks was analyzed at echocardiographic follow-up. Results. A total of 196 patients with AF underwent LAAC with the ACP (n = 99) or Amulet device (n = 97). The use of Amulet was associated with significantly lower fluoroscopy time (14.8 ± 7.4 min versus 10.6 ± 4.1 min; p < 0.001), lower radiation dose (4833 ± 3360 cGy•cm² versus 3206 ± 2169 cGy•cm²; p < 0.001), and reduced amount of contrast-dye (150.2 ± 83.9 ml versus 128.8 ± 46.0 ml; p = 0.03). Furthermore, LAAC with Amulet devices resulted in lower device-resizing rates (3 versus 16 cases; p = 0.001). Peridevice leaks were less frequent in the Amulet group (12 versus 4; p = 0.03). MAE occurred in 6 ACP and 4 Amulet patients (p = 0.58).

Conclusions. The Amulet device is associated with shorter fluoroscopy times and radiation dosages, reduced use of contrast-dye, lower recapture rates, and less peridevice leaks as compared to the ACP.

1. Introduction

The most important complication of patients with non-rheumatic atrial fibrillation (AF) is thromboembolism [1]. Percutaneous closure of the left atrial appendage (LAAC) has been considered a valid alternative to oral anticoagulation therapy for stroke prevention in these patients [2–4]. However, LAAC is still associated with a significant rate of complications, such as pericardial effusion, periprocedural stroke, device embolization, and device thrombosis [5, 6]. Therefore, manufacturers are trying to improve the design of the closure devices to reduce the rate of complications and simplify the implantation procedure.

More recently, St. Jude Medical (Minneapolis, MN, USA) has redesigned the first-generation occlusion device, the AMPLATZER Cardiac Plug (ACP), and introduced the AMPLATZER Amulet [7].

In spite of the same basic structure with a distal lobe and a proximal disc conceived for sealing the body and ostium of the LAA, respectively, the new device has particular features, which are supposed to facilitate the implantation process, improve sealing performance, and further reduce the rate of complications [8]. Smaller studies on the comparison of the older ACP and the new AMPLATZER Amulet device show conflicting data. Abualsaud et al. demonstrated in a study with a total of 59 patients similar procedural and short-term clinical outcome for both devices, whereas peridevice leaks were less frequent with the AMPLATZER Amulet device [9]. Another study with a total of 100 cases failed to show a difference between both devices [10].

The aim of our study was to compare both devices in a larger cohort to

(1) evaluate the periprocedural outcome;
(2) assess the implantation process, comparing procedure time, radiation dosage, and amount of contrast agent given;
(3) evaluate the long term transesophageal echocardiographic outcome.

2. Methods

2.1. Study Population. A total of 196 consecutive patients with AF and contraindication to effective OAC, who underwent LAAC with the ACP (n = 99) and the AMPLATZER Amulet (n = 97) between July 2014 and April 2016 at the St. Marien Hospital Bonn, were enrolled in the study.

The procedural performance and angiographic parameters, as well as the clinical outcome and echocardiographic follow-up data of all patients, were collected prospectively and analyzed.

Patient demographics and clinical characteristics, including the CHA2DS2-VASc score and the HASBLED score, were assessed for each patient.

2.2. Comparison between the ACP and the AMPLATZER Amulet. Both, first- and second-generation AMPLATZER devices for LAA occlusion are self-expanding devices with a distal lobe and a proximal disc connected by a waist and made from a nitinol mesh. While the distal lobe adapts to the inner LAA wall in the depths, the proximal disk covers the LAA ostium [11].

The second-generation AMPLATZER Amulet has some important modifications, trying to simplify the implantation procedure and to improve the occlusion of the LAA:

The AMPLATZER Amulet is now preloaded inside the delivery system, potentially reducing the risk of air embolization.

The length of the distal lobe is extended in the new devices by 2 to 3 mm, making the distal body more voluminous and better sealing. Furthermore, the increased number of the stabilizing hooks from 6 pairs in the ACP up to 10 pairs in Amulet devices, which also became stiffer now, is intended to reduce device embolization.

Concerning an optimal occlusion of the LAA ostium, the diameter of the proximal disc has been enlarged in the new device, now being 6 to 7 mm greater than the distal lobe diameter. The waist between the proximal disc and distal lobe has also been extended.

In addition, the attaching screw-nut on the disc has been inverted to reduce the occurrence of device thrombosis. Besides, the new AMPLATZER Amulet is available in larger sizes and has a new single-piece cable design for ease of delivery and better control (AMPLATZER Amulet Left Atrial Appendage Occluder Instructions for Use, St. Jude Medical, Minnesota, USA) [7, 8].

2.3. Implantation of the Device. The LAAC procedure was performed in all patients under general anesthetics using the ACP (n = 99) and the AMPLATZER Amulet (n = 96). The implantation was guided by contrast angiography and periprocedural transesophageal echocardiography (TEE) (Vivid E9, GE Medical Systems, Milwaukee, WI, USA), as described previously [5].

The size of the device was determined on the basis of a combination of maximum diameter of the intended landing zone (LZ) on two-dimensional TEE (2DTEE) and contrast angiography as recommended by the manufacturer’s instructions for use, as well as visual assessment of the LAA (AMPLATZER Cardiac Plug, AMPLATZER Amulet Left Atrial Appendage Occluder Instructions for Use, St. Jude Medical, Minnesota, USA).

The angiographic assessment of the maximum LZ diameter was performed in the (RAO 30°/10°) cranial and in the caudal view. In the 2DTEE, the maximum diameter at the LZ was obtained in different planes (from 0° to 150° in 30° increments). It was measured from the origin of the left circumflex coronary artery to the roof of the LAA, 1 cm inward from the apex of the ridge separating LAA, and left superior pulmonary vein.

After deployment of the closure device, device stability and position were tested with contrast angiography and TEE. Further details regarding LAAC procedure and special features of the ACP and AMPLATZER Amulet device have been published previously [7, 12].

2.4. Angiographic Assessment of the Implantation Procedure. During all LAAC procedures, the time from the beginning of the procedure to the extubation of the patients has been documented. The fluoroscopy time (min) and the radiation dose (cGy·cm²), as well as the amount of contrast-dye (ml) given were recorded in all patients using the DAVID® hemodynamic software (Metek, Germany). If the device was recaptured or resized, it was also documented.

2.5. Periprocedural Adverse Events. According to the VARC criteria, the collection of the periprocedural adverse events included death, myocardial infarction, stroke, transient ischemic attack (TIA), systemic embolization, air embolization, device embolization, significant pericardial effusion or cardiac tamponade, and major bleeding [13, 14]. Regarding the safety of the procedure, major adverse events (MAEs) were defined as a composite of periprocedural death, stroke, systemic embolism, and procedure or device-related complications needing major intervention.

2.6. Echocardiographic Follow-Up of the Patients. A follow-up TEE was performed 2–6 months after LAAC to assess the closure device stability and to detect potential thrombus and/or peridevice leaks. Therefore, the LAA was systematically scanned in multiple views using color Doppler at the lowest possible Nyquist limit [14]. The observed leaks were classified according to the width of the color jet-flow as previously published: minor leak (jet-flow < 1 mm), moderate leak (jet-flow = 1–3 mm), major leak (jet-flow > 3 mm), or severe leak (multiple jets or free flow) [5, 6].

2.7. Statistics. Continuous variables are presented as mean ± standard deviation (SD) and were tested via paired or unpaired Student’s t-tests. Statistics of categorical variables are presented as absolute numbers and percentages. Fisher exact test was used to assess differences in categorical variables.
Table 1: Patient characteristics.

|                                      | ACP  | Amulet | p    |
|--------------------------------------|------|--------|------|
|                                       | n (%) or value (n = 99) | n (%) or value (n = 97) |
| Age (years)                          | 75 ± 6 | 74 ± 11 | 0.36 |
| Age ≥ 75 (years)                     | 56 (57) | 53 (55) | 0.85 |
| Male                                 | 63 (64) | 57 (59) | 0.43 |
| Body mass index (kg/m²)              | 27.2 ± 5.4 | 27.8 ± 5.5 | 0.43 |
| CHA²DS²VASC score                    | 4.5 ± 1.6 | 4.5 ± 1.6 | 0.90 |
| HASBLED score                        | 3.4 ± 0.9 | 3.5 ± 0.9 | 0.44 |
| Atrial fibrillation                  |       |        |      |
| Paroxysmal/persistent                | 41 (41) | 53 (55) | 0.06 |
| Permanent AF                         | 58 (59) | 44 (45) | 0.06 |
| Clinical features                    |       |        |      |
| Coronary artery disease              | 43 (43) | 46 (47) | 0.58 |
| Myocardial infarction                | 19 (19) | 16 (16) | 0.62 |
| PCI                                  | 24 (24) | 29 (30) | 0.38 |
| CABG                                 | 13 (13) | 9 (9)   | 0.40 |
| CMP                                  | 12 (12) | 13 (13) | 0.79 |
| Arterial hypertension                | 94 (95) | 91 (94) | 0.73 |
| Diabetes mellitus                    | 26 (26) | 34 (35) | 0.18 |
| Hyperlipidemia                       | 45 (45) | 47 (48) | 0.68 |
| Creatinine                           | 1.34 ± 0.8 | 1.39 ± 0.8 | 0.68 |
| Quick                                | 87.3 ± 24.5 | 88.9 ± 26.8 | 0.67 |
| INR                                  | 1.15 ± 0.3 | 1.17 ± 0.4 | 0.63 |
| PTT (sec)                            | 27.9 ± 4.7 | 28.6 ± 6.3 | 0.44 |
| Nicotine                             | 31 (31) | 24 (25) | 0.31 |
| Medication before LAA occlusion      |       |        |      |
| Clopidogrel                          | 23 (23) | 14 (14) | 0.12 |
| Vitamin K antagonist                 | 20 (20) | 34 (35) | 0.02 |
| New oral anticoagulant drug          | 19 (19) | 29 (30) | 0.08 |
| Low molecular weight heparin         | 47 (47) | 18 (19) | <0.001 |
| Beta-blocker                         | 84 (85) | 72 (74) | 0.06 |
| Statin therapy                       | 43 (43) | 42 (43) | 0.99 |
| Diuretics                            | 63 (64) | 65 (67) | 0.62 |
| ACE inhibitor                         | 42 (42) | 33 (34) | 0.23 |
| Risk factors for bleeding            |       |        |      |
| Previous stroke/TIA                  | 31 (31) | 35 (36) | 0.48 |
| Prior major bleeding                 | 47 (48) | 50 (52) | 0.57 |
| Renal disease                        | 31 (31) | 33 (34) | 0.69 |
| Liver disease                        | 5 (5)   | 6 (6)   | 0.73 |
| Labile INR                           | 5 (5)   | 0 (0)   | 0.03 |
| Age > 65                             | 91 (92) | 84 (87) | 0.23 |

Statistical significance was considered as a 2-tailed probability value <0.05. Statistical analyses were performed with SPSS version 23 (IBM Corp., Armonk, NY, USA).

3. Results

A total of 196 consecutive patients undergoing LAAC, 99 with ACP from August 2010 to October 2014 and 97 with the Amulet from October 2014 to April 2016, were enrolled in the study. The baseline characteristics of the two patients groups are summarized in Table 1.

There were no significant differences between both groups, except for the medication before LAA occlusion: patients in the ACP group received more often low molecular weight heparin as antithrombotic therapy, whereas patients
Table 2: Indications for left atrial appendage occlusion.

| Indication                              | ACP    | Amulet   | \( p \) |
|-----------------------------------------|--------|----------|---------|
| Previous major bleeding                 | 47 (47)| 50 (52)  | 0.57    |
| Intracranial bleeding                   | 15 (15)| 18 (19)  | 0.53    |
| Gastrointestinal bleeding               | 27 (27)| 22 (23)  | 0.46    |
| Other                                   | 5 (5)  | 9 (9)    | 0.25    |
| Previous minor bleeding                 | 42 (42)| 30 (31)  | 0.10    |
| Gastrointestinal bleeding               | 21 (21)| 11 (11)  | 0.06    |
| Hematoma                                | 6 (6)  | 10 (10)  | 0.28    |
| Other                                   | 15 (15)| 9 (9)    | 0.21    |
| Renal or hepatic disease                | 34 (34)| 34 (35)  | 0.92    |
| High risk of falls or prior falls       | 9 (9)  | 5 (5)    | 0.29    |
| Physician/patient refusal of oral anticoagulation | 0 (0) | 2 (2)    | 0.15    |

For some patients, more than 1 indication was reported.

Table 3: Procedural data.

|                     | ACP       | Amulet    | \( p \) |
|---------------------|-----------|-----------|---------|
| Procedural success  | 96 (97)   | 97 (100)  | 0.08    |
| Procedure time (min)| 82 ± 28   | 75.9 ± 23 | 0.09    |
| Contrast medium (ml)| 150.2 ± 83.9 | 128.8 ± 46.0 | 0.03 |
| Fluoroscopy time (min)| 14.8 ± 7.4 | 10.6 ± 4.1 | <0.001 |
| Radiation dose (cGy*cm²)| 4833 ± 3360 | 3206 ± 2169 | <0.001 |
| More than 1 device tried | 16 (17) | 3 (3)    | 0.001   |
| Larger device finally implanted | 5 (5) | 1 (1) | 0.10 |
| Smaller device finally implanted | 11 (11) | 2 (2) | 0.01 |
| Hospital stay (days) | 6.5 ± 5  | 5.9 ± 4   | 0.37    |

The use of the AMPLATZER Amulet was associated with a significant reduction of the fluoroscopy time (14.8 ± 7.4 min for ACP versus 10.6 ± 4.1 min for Amulet; \( p < 0.001 \)) and the radiation dose (4833 ± 3360 cGy*cm² for ACP versus 3206 ± 2169 cGy*cm² for Amulet; \( p < 0.001 \)).

The medium of contrast agent given was also lower in the Amulet group, as compared to the ACP group (150.2 ± 83.9 ml for ACP versus 128.8 ± 46.0 ml for Amulet; \( p = 0.03 \)).

Moreover, recapturing and resizing of the initial selected device size was significantly less necessary in the Amulet group, counting 3 cases (3%) compared to 16 cases (17%; \( p = 0.001 \)) in the ACP group.

However, the total procedural time did not differ significantly in both groups (\( p = 0.09 \)).

3.1. Implantation of the Device and Angiographic Assessment of the Procedure. Table 3 presents the periprocedural data of both groups: the implantation of the ACP device was successful in 96 patients (97%), compared to a successful implantation of the Amulet device in 97 patients (100%) (\( p = 0.08 \)).

3.2. Periprocedural Adverse Events. The occurrence of major adverse events was comparable in both groups as shown in Table 4 (\( p = 0.58 \)).

The implantation of the ACP device led to 6 MAEs, including two patients with major bleeding and a patient with in-hospital stroke. The only two procedure-related deaths in the Amulet group were treated more frequently with coumarin derivatives (\( n = 47 \) for ACP versus \( n = 18 \) for Amulet, \( p < 0.001 \); \( n = 20 \) for ACP versus \( n = 34 \) for Amulet, \( p = 0.02 \), resp.).

However, the mean CHA₂DS₂-VASc score (4.5 for ACP and Amulet; \( p = 0.9 \)) and the mean HASBLED score (3.4 for ACP versus 3.5 for Amulet; \( p = 0.44 \)) did not differ significantly.

The main indication for LAAC in both groups was previous major bleeding (\( n = 47 \) (47%) for ACP versus \( n = 50 \) (52%) for Amulet; \( p = 0.57 \)), followed by previous minor bleeding (\( n = 42 \) (42%) for ACP versus \( n = 30 \) (31%) for Amulet; \( p = 0.10 \)) and renal or hepatic disease (\( n = 34 \) (34%) for ACP versus \( n = 34 \) (35%) for Amulet; \( p = 0.92 \))—none presented significant difference (Table 2).
Table 4: Periprocedural adverse events.

| Event                                                         | ACP   | Amulet  | p    |
|---------------------------------------------------------------|-------|---------|------|
|                                                                | n (%) | n (%)   |      |
|                                                                | (n=99) | (n=97)  |      |
| Major adverse events                                          |       |         |      |
| Death                                                         | 2 (2) | 0 (0)   | 0.16 |
| Pulseless electrical activity                                 |       |         |      |
| Device embolization requiring surgery and leading to bleeding |       |         |      |
| complication                                                  |       |         |      |
| Procedure                                                     | Day 7 |         |      |
| Stroke                                                        | 1 (1) | 0 (0)   | 0.32 |
| Systemic embolism                                             | 0 (0) | 0 (0)   | 1    |
| Myocardial infarction                                         | 0 (0) | 0 (0)   | 1    |
| Cardiac tamponade                                             | 0 (0) | 1 (1)   | 0.31 |
| Major bleeding                                                | 2 (2) | 3 (3)   | 0.64 |
| Intracranial bleeding                                         | 1 (1) | 0 (0)   | 0.32 |
| Gastrointestinal                                              | 0 (0) | 2 (2)   | 0.15 |
| Epistaxis requiring blood transfusion due to M. Osler         | 1 (1) | 1 (1)   | 0.99 |
| Device embolization requiring surgery                         | 1 (1) | 0 (0)   | 0.32 |
| Device embolization snared                                    | 0 (0) | 0 (0)   | 1    |
| Need for surgery                                              | 0 (0) | 0 (0)   | 1    |
| Total                                                         | 6 (6) | 4 (4)   | 0.58 |
| Other adverse events                                          |       |         |      |
| TIA                                                           | 0 (0) | 0 (0)   | 1    |
| Air embolism (transient ST elevation and/or chest pain)       | 0 (0) | 0 (0)   | 1    |
| Vascular complication                                         | 3 (3) | 3 (3)   | 0.98 |
| Femoral artery pseudoaneurysm                                | 3 (3) | 1 (1)   | 0.32 |
| Arteriovenous fistula                                         | 0 (0) | 2 (2)   | 0.15 |
| Total                                                         | 3 (3) | 3 (3)   | 0.98 |

were reported in the ACP group, one due to device embolization requiring surgery and the other due to periprocedural pulseless electrical activity.

In the Amulet group, a total of 4 MAEs were notified, mainly driven by major bleeding (n = 3 (3%)). In one case, a procedure-related cardiac tamponade with need for drainage was observed.

Regarding other adverse events, the ACP and the AMPLATZER Amulet implantation were each associated with 3 vascular complications, such as femoral artery pseudoaneurysm and arteriovenous fistula (p = 1).

3.3. Transesophageal Echocardiographic Follow-Up. Follow-up TEE was performed in 81 patients (82%) in the ACP group and in 82 patients (85%) in the Amulet group. The mean time duration between the implantation procedure and the first TEE examination was 3.1 ± 6 months for ACP and 2.3 ± 1.5 months for Amulet (p = 0.33). As shown in Table 5, none of the patients presented device embolization.

Peridevice leaks were significantly more frequent in patients with ACP devices, counting 12 cases with minor leaks at follow-up TEE compared to 4 minor leaks in the Amulet group (p = 0.03). Moreover, the use of Amulet was associated with a reduced rate of device-related thrombus, counting only one Amulet case compared to 4 ACP cases, although not reaching significance (p = 0.17).

Table 5: Prevalence and severity of peridevice leaks at transesophageal echocardiographic follow-up.

| Peridevice leakage | ACP | Amulet | p    |
|--------------------|-----|--------|------|
|                    | n (%) | n (%) |      |
|                    | (n=81) | (n=82) |      |
| Device-related thrombus | 4 (5) | 1 (1) | 0.17 |
| Device embolization | 0 (0) | 0 (0) | 1    |
| Peridevice leakage | 12 (15) | 4 (5) | 0.03 |
| Severe leaks       | 0 (0) | 0 (0) | 1    |
| Major leak         | 0 (0) | 0 (0) | 1    |
| Moderate leak      | 0 (0) | 0 (0) | 1    |
| Minor leak         | 12 (15) | 4 (5) | 0.03 |

4. Discussion

The major results of the present study with a total of 196 consecutive patients undergoing LAAC with the first and second generation AMPLATZER devices are as follows:

(1) The new AMPLATZER Amulet device simplifies the implantation procedure, resulting in significantly shorter fluoroscopy time, less radiation dosage, and a reduced use of contrast-dye.
(2) Recapturing and resizing of the occlusion device was significantly lower with the new Amulet device.

(3) The use of the AMPLATZER Amulet was associated with a significant reduction of peridevice leaks at follow-up as compared with the ACP.

4.1. Procedural Data. Procedural success is generally high with all LAAC devices [15].

Hence our finding of a success rate of 97% for the ACP device and 100% for the Amulet device is in congruence with previous reports [5–7]. Since the rate of success was very high, a statistical difference between both groups is not detectable. This is in agreement with the findings of Gloekler et al., who compared the ACP and Amulet device in a dual-center cohort study of 100 consecutive patients [10].

However, Gloekler et al. did not report on angiographic assessment of the procedure, such as fluoroscopy time and radiation dosage.

We could show that fluoroscopy time was reduced by 28.4% and radiation dosage by 33.6% with the use of the newer device. In concordance to the short fluoroscopy time, the applied amount of contrast agent was 14.2% lower with the Amulet device as compared to the ACP device. This is partly due to the fact that recapturing and resizing of the newer device was only necessary in 3% of cases.

The latter finding is of particular importance, since recapturing and resizing of the device may potentially harm the left atrial appendage.

Since we perform our procedures in general anesthesia, the total duration of the procedure is also influenced by the duration of anesthesia. Hence we did not find a significant difference between both groups.

In addition to the improved implant profile in experienced operators, these findings might also be explained by the modifications of the newer Amulet device improving technical success of the device implantation: the extended body of the device with increased number of the stabilizing hooks may simplify the proper apposition of the device in the LAA and provide more stability.

4.2. Periprocedural Adverse Events. In concordance to previous publications, the occurrence of periprocedural major adverse events was low in both groups [10]. There were 6 (6%) events in the ACP group and 4 (4%) in the Amulet group. Of interest 3 out of the 4 events in the Amulet group were periprocedural major bleedings not directly related to implantation process. We observed only 1 pericardial tamponade in the Amulet group. Despite the trend of lower rates of major complications in the Amulet group, a statistical difference between both groups is not detectable.

4.3. Echocardiographic Follow-Up. The TEE follow-up examination showed 4 (5%) thrombi on the device in the ACP group. This is very similar to the finding of Apostolos et al. reporting on 4.4% of thrombi related to the ACP device [5]. Of interest is our observation that only 1 patient in the Amulet group had a thrombus on the device 2 months after implantation. This difference is not statistically significant. However, there is a signal that the larger disc and the embedded screw-nut may potentially reduce thrombus formation on the device.

In concordance with Tzikas et al., we could demonstrate that the use of Amulet device is associated with a significant reduction of perdevice leaks at follow-up TEE examination as compared to the ACP devices [9]. However, the number of perdevice leaks was high in his study, detecting 48% of leaks in the ACP group compared to 8% in the Amulet group. The much larger study on the multicenter experience with the ACP with 1001 patients reported only 11.6% of perdevice leaks [5].

In our series, 15% of the patients with ACP devices and 5% of the patients with Amulet devices presented perdevice leaks, which is in agreement with the larger study. Interestingly all of our perdevice leaks occurring in both groups were minor leaks.

Our finding supports the assumption that the enlarged and more voluminous distal lobe improves sealing performance of the inner LAA in the depths, while the extended diameter of the proximal disc may enhance the covering of the LAA ostium.

5. Conclusions

The aims of the development of a second-generation occluder with some important modifications were to improve the implantation process and to further enhance the implantation safety.

The present article shows a better procedural performance of the newer AMPLATZER Amulet device with significantly reduced radiation dosage, fluoroscopy time, and amount of contrast agent given.

Moreover, the reduced occurrence of device-related thrombus and perdevice leaks with the Amulet might be a result of an improved sealing performance due to the extended distal body with enhanced anchoring and the enlarged disc with inverted screw-nut.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

References

[1] “Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials,” Archives of Internal Medicine, vol. 154, pp. 1449–1457, 1994.
[2] H. Omran, D. Hardung, H. Schmidt, C. Hammerstingl, and B. Lüderitz, “Mechanical occlusion of the left atrial appendage,” Journal of Cardiovascular Electrophysiology, vol. 14, no. 9, pp. S56–S59, 2003.
[3] B. Meier, Y. Blaauw, A. A. Khattab et al., “EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion,” Europace, vol. 16, no. 10, pp. 1397–1416, 2014.
[4] D. R. Holmes, V. Y. Reddy, Z. G. Turi et al., “Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a
randomised non-inferiority trial,” *The Lancet*, vol. 374, no. 9689, pp. 534–542, 2009.

[5] A. Tzikas, S. Shakir, S. Gafoor et al., “Left atrial appendage occlusion for stroke prevention in atrial fibrillation: Multicentre experience with the AMPLATZER Cardiac Plug,” *EuroIntervention*, vol. 11, no. 10, pp. 1170–1179, 2016.

[6] S. Ostermayer, M. Reisman, P. Kramer et al., “Percutaneous left atrial appendage transcatheter occlusion (PLAATO System) to prevent stroke in high-risk patients with non-rheumatic atrial fibrillation: results from the international Multi-Center Feasibility Trials,” *Journal of the American College of Cardiology*, vol. 46, pp. 9–14, 2005.

[7] X. Freixa, A. Abualsaud, J. Chan et al., “Left atrial appendage occlusion: initial experience with the Amplatzer Amulet,” *International Journal of Cardiology*, vol. 174, no. 3, pp. 492–496, 2014.

[8] X. Freixa, J. L. K. Chan, A. Tzikas, P. Garceau, A. Basmadjian, and R. Ibrahim, “The Amplatzer™ cardiac plug 2 for left atrial appendage occlusion: novel features and first-in-man experience,” *EuroIntervention*, vol. 8, no. 9, pp. 1094–1098, 2013.

[9] A. Abualsaud, X. Freixa, A. Tzikas et al., “Side-by-Side Comparison of LAA Occlusion Performance with the Amplatzer Cardiac Plug and Amplatzer Amulet,” *Journal of Invasive Cardiology*, vol. 28, no. 1, pp. 34–38, 2016.

[10] S. Gloekler, S. Shakir, J. Doblies et al., “Early results of first versus second generation Amplatzer occluders for left atrial appendage closure in patients with atrial fibrillation,” *Clinical Research in Cardiology*, vol. 104, no. 8, pp. 656–665, 2015.

[11] X. Freixa, A. Tzikas, A. Sobrino, J. Chan, A. J. Basmadjian, and R. Ibrahim, “Left atrial appendage closure with the Amplatzer™ Cardiac Plug: Impact of shape and device sizing on follow-up leaks,” *International Journal of Cardiology*, vol. 168, no. 2, pp. 1023–1027, 2013.

[12] J. W. Park, A. Bethencourt, H. Sievert et al., “Left atrial appendage closure with Amplatzer cardiac plug in atrial fibrillation: initial European experience,” *Catheterization and Cardiovascular Interventions*, vol. 77, no. 5, pp. 700–706, 2011.

[13] A. P. Kappetein, S. J. Head, P. Genereux, and N. Piazza, “Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document,” *Journal of the American College of Cardiology*, vol. 60, pp. 1438–1454, 2012.

[14] A. Tzikas, D. R. Holmes, S. Gafoor et al., “Percutaneous left atrial appendage occlusion: the Munich consensus document on definitions, endpoints and data collection requirements for clinical studies,” *EuroIntervention*, vol. 12, no. 1, pp. 103–111, 2016.

[15] D. R. Holmes, Kar Jr., M. J. Price, B. Whisenant, and H. Sievert, “Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial,” *Journal of the American College of Cardiology*, vol. 64, pp. 1–12, 2014.